These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 35130836

  • 1. Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.
    Lipton RB, Charleston L, Tassorelli C, Brevig T, Hirman J, Cady R.
    J Headache Pain; 2022 Feb 07; 23(1):23. PubMed ID: 35130836
    [Abstract] [Full Text] [Related]

  • 2. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R.
    Headache; 2021 May 07; 61(5):766-776. PubMed ID: 34013992
    [Abstract] [Full Text] [Related]

  • 3. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
    Starling AJ, Cowan RP, Buse DC, Diener HC, Marmura MJ, Hirman J, Brevig T, Cady R.
    Headache; 2023 Feb 07; 63(2):264-274. PubMed ID: 36633219
    [Abstract] [Full Text] [Related]

  • 4. Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.
    Apelian R, Boyle L, Hirman J, Asher D.
    J Headache Pain; 2022 Apr 18; 23(1):48. PubMed ID: 35436857
    [Abstract] [Full Text] [Related]

  • 5. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
    Cowan RP, Marmura MJ, Diener HC, Starling AJ, Schim J, Hirman J, Brevig T, Cady R.
    J Headache Pain; 2022 Sep 06; 23(1):115. PubMed ID: 36068494
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R.
    Headache; 2021 Jan 06; 61(1):125-136. PubMed ID: 33314079
    [Abstract] [Full Text] [Related]

  • 7. Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache.
    Blumenfeld A, Kudrow D, McAllister P, Boserup LP, Hirman J, Cady R.
    Headache; 2024 Jan 06; 64(7):738-749. PubMed ID: 38924044
    [Abstract] [Full Text] [Related]

  • 8. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
    McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R.
    J Headache Pain; 2022 Feb 07; 23(1):22. PubMed ID: 35130832
    [Abstract] [Full Text] [Related]

  • 9. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R.
    Headache; 2021 Oct 07; 61(9):1421-1431. PubMed ID: 34551130
    [Abstract] [Full Text] [Related]

  • 10. Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.
    Buse DC, Winner PK, Charleston L, Hirman J, Cady R, Brevig T.
    J Headache Pain; 2022 Feb 21; 23(1):29. PubMed ID: 35189811
    [Abstract] [Full Text] [Related]

  • 11. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.
    Martin V, Nagy AJ, Janelidze M, Giorgadze G, Hirman J, Cady R, Mehta L, Buse DC.
    Clin Ther; 2022 Mar 21; 44(3):389-402. PubMed ID: 35131090
    [Abstract] [Full Text] [Related]

  • 12. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
    Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J.
    J Headache Pain; 2020 Oct 06; 21(1):120. PubMed ID: 33023473
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
    Ashina M, McAllister P, Cady R, Hirman J, Ettrup A.
    Cephalalgia; 2022 Jul 06; 42(8):696-704. PubMed ID: 35302389
    [Abstract] [Full Text] [Related]

  • 14. Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
    Schim JD, Anderson C, Brunner E, Hirman J, Ogbru A, Cady R, McGill L.
    Headache; 2022 May 06; 62(5):558-565. PubMed ID: 35524405
    [Abstract] [Full Text] [Related]

  • 15. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
    Ailani J, McAllister P, Winner PK, Chakhava G, Krog Josiassen M, Lindsten A, Sperling B, Ettrup A, Cady R.
    BMC Neurol; 2022 Jun 03; 22(1):205. PubMed ID: 35659622
    [Abstract] [Full Text] [Related]

  • 16. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
    Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B.
    Eur J Neurol; 2023 Apr 03; 30(4):1089-1098. PubMed ID: 36583633
    [Abstract] [Full Text] [Related]

  • 17. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.
    Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB.
    Headache; 2020 Oct 03; 60(9):2003-2013. PubMed ID: 32862469
    [Abstract] [Full Text] [Related]

  • 18. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
    Pozo-Rosich P, Dodick DW, Ettrup A, Hirman J, Cady R.
    BMC Neurol; 2022 Oct 25; 22(1):394. PubMed ID: 36284281
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ, Bose R, Jion YI.
    Headache; 2024 Oct 25; 64(7):810-824. PubMed ID: 38785386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.